Table 1.

Baseline characteristics of moderate-to-severe UC patients using first-line and second-line infliximab or vedolizumab.

Biological agent	Infliximab n = 251	Vedolizumab n = 169	p-value
Male, n (%)	136 (54.2%)	84 (49.7%)	0.38
Median age, years (IQR)	37.0 (28.0–54.0)	44.0 (33.0–56.0)	0.003
Immunomodulator co-therapy, n (%)	160 (63.7%)	80 (47.3%)	0.001
Thiopurine, n (%)	145 (57.8%)	75 (44.4%)	0.01
Methotrexate, n (%)	21 (8.4%)	7 (4.1%)	0.09
Time on combination therapy between biological agent and immunomodulator, months (IQR)	17.3 (5.1–27.6)	13.3 (3.6–17.5)	0.03

IQR, interquartile range; UC, ulcerative colitis.